Kidney cancer treatment before surgery
Treatments studied
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests two drugs, alone or together, given before surgery to shrink kidney cancer tumors. It aims to see which approach works best for patients with intermediate- to high-risk clear cell renal cell carcinoma.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with clear cell renal cell carcinoma, a type of kidney cancer.
- Your cancer is considered intermediate-high risk, high risk, or has spread to certain nearby areas or soft tissue.
- You are scheduled to have surgery to remove the kidney tumor.
- You are at least 18 years old.
- You are in generally good health (able to care for yourself), with no serious heart or lung problems.
- You have not had previous chemotherapy or radiation for your kidney cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two immunotherapy drugs (botensilimab and balstilimab) given before surgery to remove a kidney tumor. The goal is to see if this approach is safe and helps shrink tumors in patients with advanced but non-spreading kidney cancer.
This trial tests giving two medications (a PD-L1 inhibitor and anlotinib) before surgery for complex kidney cancer, to try to shrink the tumor enough that surgeons can remove just part of the kidney instead of the whole organ. The goal is to preserve kidney function and avoid dialysis.
This trial is testing if adding the targeted therapy tivozanib to the immunotherapy drug pembrolizumab (Keytruda) can help prevent kidney cancer from coming back after all known tumors have been removed by surgery.
This trial tests a new drug combination given before surgery for kidney cancer that is early stage but hard to operate on. The goal is to shrink the tumor and make surgery easier.
This trial is testing whether adding a gut health supplement (CBM588) to the immunotherapy drug pembrolizumab can help prevent kidney cancer from returning after surgery. It is for people with certain types of kidney cancer who have not had immunotherapy before.
This trial tests a combination of two drugs, zanzalintinib and pembrolizumab, given before surgery for clear cell kidney cancer that has not spread too far. The goal is to see if the drugs help shrink the tumor and make surgery more effective.
Hear when a new Clear Cell Renal Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.